Collins Stewart Cuts Price Target on Genzyme (GENZ) to $63, But Reiterates Buy
Tweet Send to a Friend
Collins Stewart lowers it's price target on Genzyme (Nasdaq: GENZ) from $67 to $63, reiterating its Buy rating.
The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
